Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2

Vaccine

Volumn 33, Issue 29, 2015, Pages 3346-3353

  Tumban, Ebenezer ^a   Muttil, Pavan ^b   Escobar, Carolina Andrea A ^a   Peabody, Julianne ^a   Wafula, Denis ^b   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Adjuvants; Formulation; HPV vaccine; MS2 and PP7 bacteriophages; Virus like particles

Indexed keywords

AMINO ACID; CAPSID PROTEIN; CAPSID PROTEIN 16L2 MS2 VIRUS LIKE PARTICLE; CARBOHYDRATE; EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRY POWDER; ENTEROBACTERIA PHAGE MS2; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; SINGLE DRUG DOSE; SPRAY DRYING; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL SURFACE DISPLAY; CROSS REACTION; DRUG STABILITY; GENETICS; IMMUNOLOGY; LEVIVIRUS; MEDICINAL CHEMISTRY; PROCEDURES; TEMPERATURE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL SURFACE DISPLAY TECHNIQUES; CHEMISTRY, PHARMACEUTICAL; CROSS REACTIONS; DRUG STABILITY; FEMALE; LEVIVIRUS; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; TEMPERATURE; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84931576072     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.016     Document Type: Article

References (33)

1. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4301.
2. McLaughlin-Drubin M.E., Meyers J., Munger K. Cancer associated human papillomaviruses. Curr Opin Virol 2012, 2:459-466.
3. Kim K.S., Park S.A., Ko K.N., Yi S., Cho Y.J. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014, 3:168-175.
4. Schiller J.T., Lowy D.R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012, 10:681-692.
5. Tyler M., Tumban E., Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines 2014, 13:247-255.
6. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
7. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
8. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3:109-115.
9. Tyler M., Tumban E., Dziduszko A., Ozbun M.A., Peabody D.S., Chackerian B. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine 2014, 32:4267-4274.
10. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
11. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
12. Merck Merck newsroom 2015, [updated Dec. 11, 2014]. Available from: 〈http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an〉 (accessed Jan. 15, 2015).
13. Schiller J.T., Nardelli-Haefliger D. Second generation HPV vaccines to prevent cervical cancer. Vaccine 2006, 24(Suppl. 3 (S3)):147-153. Chapter 17.
14. Chen D., Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines 2009, 8:547-557.
15. Tumban E., Peabody J., Peabody D.S., Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE 2011, 6:e23310.
16. Tumban E., Peabody J., Peabody D.S., Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 2013, 3(41):4647-4654.
17. Tumban E., Peabody J., Tyler M., Peabody D.S., Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS ONE 2012, 7:e49751.
18. Tyler M., Tumban E., Peabody D.S., Chackerian B. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng 2014, 111:2398-2406.
19. Muttil P., Pulliam B., Garcia-Contreras L., Fallon J.K., Wang C., Hickey A.J., et al. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J 2010, 12:699-707.
20. Caldeira Jdo C., Medford A., Kines R.C., Lino C.A., Schiller J.T., Chackerian B., et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010, 28:4384-4393.
21. Buck C.B., Thompson C.D., Pang Y.Y., Lowy D.R., Schiller J.T. Maturation of papillomavirus capsids. J Virol 2005, 79:2839-2846.
22. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 2009, 83:2067-2074.
23. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000, 203:1-60.
24. Loftus P. FDA clears new version of Merck's Gardasil Dec 2014, [cited Jan 16, 2015]. Available from: 〈http://www.wsj.com/articles/fda-clears-mercks-gardasil-to-treat-broader-range-of-cancers-1418243098〉.
25. Schellenbacher C., Kwak K., Fink D., Shafti-Keramat S., Huber B., Jindra C., et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013, 133:2706-2713.
26. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009, 101:782-792.
27. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007, 358:266-272.
28. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337:365-372.
29. Kalnin K., Tibbitts T., Yan Y., Stegalkina S., Shen L., Costa V., et al. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine 2014, 32:3540-3547.
30. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6:1242-1250.
31. Schiller J.T., Lowy D.R. Raising expectations for subunit vaccine. J Infect Dis 2014, 21(9):1373-1375.
32. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
33. Jin T.H., Tsao E., Goudsmit J., Dheenadhayalan V., Sadoff J. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine 2010, 28:4369-4375.